Literature DB >> 15251332

Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels.

F Mercanoglu1, A Turkmen, O Kocaman, B Pinarbasi, M Dursun, F Selcukbiricik, M S Sever.   

Abstract

BACKGROUND: Cyclosporine (CsA), one of the standard agents used in renal transplant recipients, has been considered to cause endothelial dysfunction and to contribute to arterial complications posttransplant. Since concentration-dependent effects of CsA on endothelial functions in humans have not been examined, this study was performed to investigate this relationship.
METHODS: Fifteen renal transplant patient and 20 healthy subjects (controls) were evaluated for brachial artery endothelial function using high-resolution vascular ultrasound just before the CsA dosage (baseline) and at the second hour after the administration. Endothelium-dependent and -independent vasodilatations (EDD and EID, respectively) were assessed by establishing of the responses to reactive hyperemia and by using sublingual nitroglycerine, respectively. CsA levels were assessed at baseline and at second hour, times when performing brachial artery measurements.
RESULTS: There were no significant differences between recipients and controls with respect to atherosclerosis risk factors. Mean EDD of recipients at baseline times were significantly less than those in controls (9.1% +/- 5.5% vs 15.2% +/- 7.2%, respectively; P < .001). CsA levels at trough and at second hour were 153.9 +/- 74.8 ng/mL and 646.8 +/- 163.2 ng/mL, respectively (P < .0001). Recipient, EDD at second hour was significantly reduced compared to baseline values (5.3% +/- 3.6% vs 9.1% +/- 5.5% respectively; P = .014) while changes in EID and in the diameter of the brachial artery between baseline and second hour were insignificant.
CONCLUSION: Endothelial dysfunction evaluated by brachial ultrasound in renal transplant recipients is closely related to CsA levels. It is more pronounced at 2 hours after CsA dosage, at the time of peak drug levels. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251332     DOI: 10.1016/j.transproceed.2004.05.073

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

Review 1.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

Review 2.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

3.  An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.

Authors:  Mark LaSpina; Sudipta Tripathi; Louis A Gatto; David Bruch; Kristopher G Maier; Dilip S Kittur
Journal:  J Surg Res       Date:  2008-01-29       Impact factor: 2.192

Review 4.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; R F Duarte; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; T Pagluica; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; E Carreras
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

Review 5.  Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Francesca Bonifazi; Francesco Barbato; Federico Ravaioli; Mariarosaria Sessa; Irene Defrancesco; Mario Arpinati; Michele Cavo; Antonio Colecchia
Journal:  Front Immunol       Date:  2020-04-03       Impact factor: 7.561

6.  Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients.

Authors:  K J Skaarud; M B Veierød; S Lergenmuller; A Bye; P O Iversen; G E Tjønnfjord
Journal:  Bone Marrow Transplant       Date:  2019-08-27       Impact factor: 5.483

7.  [Chinese expert consensus on the diagnosis and management of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (2022)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

Review 8.  Early diagnostic value of liver stiffness measurement in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation.

Authors:  You-Wen Tan; Yi-Chun Shi
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

Review 9.  Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?

Authors:  Giuseppe Lia; Luisa Giaccone; Sarah Leone; Benedetto Bruno
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.